Repurposing Paroxetine Mesylate: MET and ERBB3 Inhibition in Colorectal Cancer Cells

Study Background and Research Question

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with approximately 30% of patients presenting metastatic disease at diagnosis (source: paper). Despite advances in targeted therapies and chemotherapeutics, the high costs, modest benefits, and increasing drug resistance associated with standard treatments underscore the need for new therapeutic strategies. Drug repositioning—finding new disease targets for existing drugs—offers a promising shortcut in oncology, leveraging established clinical safety profiles to accelerate the development pipeline. Paroxetine Mesylate, a well-known selective serotonin reuptake inhibitor (SSRI), is traditionally prescribed for psychiatric disorders. Recent studies have suggested that various SSRIs may possess anticancer activities, but the underlying molecular mechanisms remain largely undefined. The reference study specifically asks: Can Paroxetine Mesylate be repurposed as an anti-colorectal cancer agent, and if so, through what molecular targets does it act?

Key Innovation from the Reference Study

The major innovation of this study lies in elucidating the dual inhibition of receptor tyrosine kinases MET and ERBB3 by Paroxetine Mesylate in CRC cells (source: paper). This mechanistic insight not only expands the pharmacological landscape of SSRIs but also identifies new actionable vulnerabilities in colorectal cancer. By targeting MET and ERBB3, Paroxetine Mesylate disrupts critical oncogenic signaling pathways, distinguishing itself from classical SSRIs and establishing a rationale for its repositioning in oncology.

Methods and Experimental Design Insights

The investigators employed a rigorous in vitro and in vivo approach:

• Colorectal cancer cell lines HCT116 and HT-29 were treated with Paroxetine Mesylate in dose- and time-dependent regimens.
• Cell viability was measured via MTT assays, while apoptosis was assessed by Annexin V/PI staining and caspase-3 activation analysis.
• Colony formation and 3D spheroid assays quantified the drug's effect on tumorigenicity and self-renewal.
• Western blotting was used to track the phosphorylation status of MET, ERBB3, and downstream signaling molecules (AKT, ERK, p38, JNK).
• For in vivo validation, athymic nude mice bearing HT-29 xenografts were treated with Paroxetine Mesylate; tumor growth was monitored longitudinally.

The combination of 2D, 3D, and animal models enabled robust cross-validation of findings, increasing confidence in the observed mechanistic effects (source: paper).

Protocol Parameters

• assay | IC₅₀ for HCT116 cell proliferation | 7–26 μM | Demonstrates effective in vitro anti-proliferative concentration range | paper
• assay | Oral dosing in xenograft models | 10 mg/kg/day | Used for tumor growth inhibition studies in mice | paper
• assay | Apoptosis quantification | Increased caspase-3 activation and Annexin V positivity | Confirms drug-induced programmed cell death | paper
• assay | 3D spheroid disruption | Complete inhibition at ≥10 μM | Models tumor self-renewal and resistance | paper
• assay | MET/ERBB3 phosphorylation | Marked suppression at 10–20 μM | Links drug action to kinase inhibition | paper
• assay | Downstream AKT/ERK/p38/JNK signaling | Inhibition of AKT/ERK/p38, induction of JNK | Mechanistic insight into anti-tumor pathways | paper
• assay | Storage stability | -20°C recommended | Ensures compound integrity for experimental reproducibility | product_spec

Core Findings and Why They Matter

Paroxetine Mesylate treatment resulted in a significant, dose-dependent reduction in CRC cell viability and colony formation. This cytotoxicity was closely associated with increased apoptosis, as evidenced by enhanced caspase-3 activity. Notably, the compound disrupted 3D spheroid formation, a model for tumor self-renewal and microenvironmental resistance (source: paper). Mechanistically, Paroxetine Mesylate inhibited phosphorylation of the receptor tyrosine kinases MET and ERBB3, leading to the suppression of downstream oncogenic signaling (AKT, ERK, p38) and induction of pro-apoptotic JNK signaling. In vivo, treated mice exhibited markedly suppressed tumor growth compared to controls, validating the translational relevance of these findings. These results position Paroxetine Mesylate not only as a selective serotonin reuptake inhibitor but also as a MET and ERBB3 kinase inhibitor with tangible anti-colorectal cancer potential (source: paper).

Comparison with Existing Internal Articles

The mechanistic insights from the reference study are echoed and further contextualized by several internal resources:

• Paroxetine Mesylate: Mechanistic Advances in Cancer Research explores the compound's dual SSRI and multi-kinase inhibition, supporting its relevance in translational oncology research. The internal review corroborates the anti-colorectal cancer activity and discusses experimental protocol strategies (source: workflow_recommendation).
• Paroxetine Mesylate Targets MET/ERBB3 in Colorectal Cancer Cells directly aligns with the reference study, highlighting dual kinase inhibition as a core mechanism, and further discusses the drug repositioning framework (source: workflow_recommendation).
• Other workflow-focused resources (e.g., Applied Research Protocols & Troubleshooting) offer practical guidance for implementing Paroxetine Mesylate in oncology and neuropharmacology models, including troubleshooting for kinase-targeted workflows.

Taken together, these resources reinforce the reference findings and facilitate efficient research translation for investigators seeking to leverage Paroxetine Mesylate in mechanistic or therapeutic studies.

Limitations and Transferability

Despite its promising preclinical efficacy, several limitations must be considered:

• The current evidence is primarily derived from cell culture and animal models; human clinical data are lacking, and direct translation to patient care is not yet established (source: paper).
• Potential off-target effects and toxicity profiles must be rigorously evaluated, given Paroxetine Mesylate's known activity as a cytochrome P450 inhibitor (notably CYP2D6), G protein-coupled receptor kinase 2 (GRK2) inhibitor, and possible interactions with other receptor tyrosine kinases (source: product_spec).
• Resistance mechanisms to MET/ERBB3 inhibition may emerge, necessitating combination strategies or biomarker-guided patient selection in future studies (workflow_recommendation).

Transferability to other cancer types, or to indications beyond oncology (e.g., cardiovascular or antiviral), requires separate validation and should not be presumed based on these findings alone.

Why this cross-domain matters, maturity, and limitations

The dual activity of Paroxetine Mesylate—as both a selective serotonin reuptake inhibitor and a multi-kinase inhibitor—enables research at the intersection of neuropharmacology and oncology. This cross-domain versatility supports experimental designs that address cancer progression alongside psychiatric comorbidities. However, the maturity of this cross-domain application remains preclinical, and further validation in clinical settings is needed to establish safety and efficacy (source: paper, workflow_recommendation).

Research Support Resources

Researchers exploring the anticancer mechanisms of Paroxetine Mesylate can utilize Paroxetine Mesylate (SKU C8698) from APExBIO, which is suitable for both in vitro and in vivo applications in colorectal cancer and kinase inhibition studies. Protocols should consider the compound's storage requirements and documented IC₅₀ ranges for optimal experimental reproducibility (source: product_spec).